<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00899158</url>
  </required_header>
  <id_info>
    <org_study_id>CASE3204</org_study_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CASE3204</secondary_id>
    <secondary_id>CWRU-020541</secondary_id>
    <nct_id>NCT00899158</nct_id>
  </id_info>
  <brief_title>Biological Markers in Patients With Pancreatic Cancer Experiencing Weight Loss</brief_title>
  <official_title>Role of Caspase-3, Phosphatidylinositol-3 Kinase (PI3K), and 3-methylhistidine (3-MH) in the Pathophysiology of Skeletal Muscle Loss in Weight-losing Pancreas Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Learning about biological markers in patients with pancreatic cancer and cachexia&#xD;
      may help doctors predict patient outcome and may help the study of cancer in the future.&#xD;
&#xD;
      PURPOSE: This laboratory study is examining biological markers in patients with pancreatic&#xD;
      cancer experiencing weight loss.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare levels of caspase-3 and phosphorylated Akt (pAkt) in the rectus abdominous&#xD;
           muscle of patients with pancreatic cancer who are experiencing cachexia and are&#xD;
           undergoing surgery for diagnosis or primary therapy with patients who have not lost&#xD;
           weight and are undergoing abdominal surgery for nonmalignant conditions.&#xD;
&#xD;
        -  Compare levels of urinary 3-methylhistidine (3-MH) in these patients.&#xD;
&#xD;
        -  Evaluate possible correlations of caspase-3 activity, pAkt, and urinary 3-MH with early&#xD;
           time to progression and subsequent lean body weight loss in patients with pancreatic&#xD;
           cancer.&#xD;
&#xD;
        -  Associate excretion of urinary 3-MH with higher levels of caspase-3 activity and pAkt to&#xD;
           analyze the utility of 3-MH as a marker of skeletal muscle proteolysis.&#xD;
&#xD;
      OUTLINE: This is a pilot study.&#xD;
&#xD;
      During surgery, a muscle biopsy is performed and approximately 1 cm of rectus abdominous&#xD;
      muscle is obtained for analysis. Caspase-3 activity and total/phosphorylated&#xD;
      phosphatidylinositol-3 kinase and Akt are measured in muscle biopsies by western blot&#xD;
      analysis. 3-methylhistidine activity is measured in urine samples.&#xD;
&#xD;
      After completion of study, patients with pancreatic cancer are followed postoperatively at 3&#xD;
      and 6 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 36 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Skeletal muscle loss</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lean body mass</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Caspase-3 levels</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phosphorylated Akt levels</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary 3-methylhistidine levels</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <enrollment type="Actual">44</enrollment>
  <condition>Cachexia</condition>
  <condition>Pancreatic Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunologic technique</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      During surgery, a muscle biopsy is performed and approximately 1 cm of rectus abdominous&#xD;
      muscle is obtained for analysis.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Primary care clinic&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Meets 1 of the following criteria:&#xD;
&#xD;
               -  Diagnosis or suspicion of pancreatic cancer&#xD;
&#xD;
                    -  Any stage disease allowed&#xD;
&#xD;
                    -  At least 5% weight loss within the past 6 months&#xD;
&#xD;
                    -  Scheduled to undergo exploratory surgery&#xD;
&#xD;
               -  Scheduled to undergo exploratory surgery for suspected nonmalignant condition&#xD;
&#xD;
                    -  No weight loss OR weight loss due to specific reason (e.g., bowel&#xD;
                       obstruction, infection, or nausea/vomiting)&#xD;
&#xD;
          -  No cancer diagnosis other than primary pancreatic carcinoma&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-3&#xD;
&#xD;
          -  Life expectancy â‰¥ 12 weeks&#xD;
&#xD;
          -  No pacemakers or implanted defibrillators&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Prior or concurrent chemotherapy and radiotherapy allowed&#xD;
&#xD;
          -  Prior or concurrent biological therapy and surgery allowed&#xD;
&#xD;
          -  At least 4 weeks since prior corticosteroids or anabolic steroids&#xD;
&#xD;
          -  Other concurrent anticancer therapy allowed&#xD;
&#xD;
          -  No concurrent corticosteroids or anabolic steroids, thalidomide, eicosapentaenoic acid&#xD;
             (EPA), or Juven for weight loss&#xD;
&#xD;
               -  Concurrent steroids (i.e., antiemetics) associated with chemotherapy allowed&#xD;
&#xD;
          -  No concurrent nutritional supplements with EPA&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanna M. Brell, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>September 29, 2015</last_update_submitted>
  <last_update_submitted_qc>September 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent pancreatic cancer</keyword>
  <keyword>stage I pancreatic cancer</keyword>
  <keyword>stage II pancreatic cancer</keyword>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <keyword>cachexia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Wasting Syndrome</mesh_term>
    <mesh_term>Cachexia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

